[go: up one dir, main page]

EA202092847A1 - Антитела к cd3 и их применение - Google Patents

Антитела к cd3 и их применение

Info

Publication number
EA202092847A1
EA202092847A1 EA202092847A EA202092847A EA202092847A1 EA 202092847 A1 EA202092847 A1 EA 202092847A1 EA 202092847 A EA202092847 A EA 202092847A EA 202092847 A EA202092847 A EA 202092847A EA 202092847 A1 EA202092847 A1 EA 202092847A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
relates
present
specifically bind
application
Prior art date
Application number
EA202092847A
Other languages
English (en)
Inventor
Франсуа Годе
Джилл Джайлс-Комар
Бредли Хайдрих
Чичи Хуан
Коллин Кейн
Ронан Макдейд
Дженнифер Немет-Сиэй
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Publication of EA202092847A1 publication Critical patent/EA202092847A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к антителам, которые специфически связывают CD3. Настоящее изобретение относится к антителам, которые специфически связывают PSMA. Настоящее изобретение относится к антителам, которые специфически связывают CD3 и PSMA. Настоящее изобретение относится к антителам, которые специфически связывают IL1RAP. Настоящее изобретение относится к антителам, которые специфически связывают CD33. Настоящее изобретение относится к антителам, которые специфически связывают CD3 и IL1RAP. Настоящее изобретение относится к антителам, которые специфически связывают CD3 и CD33. Настоящее изобретение относится к антителам, которые специфически связывают TMEFF2. Настоящее изобретение относится к антителам, которые специфически связывают CD3 и TMEFF2. Настоящее изобретение относится к фрагментам антител, полинуклеотидам, кодирующим антитела или их фрагментам, и способам их получения и применения.
EA202092847A 2018-05-24 2019-05-21 Антитела к cd3 и их применение EA202092847A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676081P 2018-05-24 2018-05-24
PCT/IB2019/054188 WO2019224717A2 (en) 2018-05-24 2019-05-21 Anti-cd3 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202092847A1 true EA202092847A1 (ru) 2021-04-20

Family

ID=67211773

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092847A EA202092847A1 (ru) 2018-05-24 2019-05-21 Антитела к cd3 и их применение

Country Status (32)

Country Link
US (2) US11603405B2 (ru)
EP (1) EP3802608B1 (ru)
JP (2) JP7530299B2 (ru)
KR (1) KR20210012007A (ru)
CN (2) CN120058941A (ru)
AR (1) AR115422A1 (ru)
AU (1) AU2019274656A1 (ru)
BR (1) BR112020023508A2 (ru)
CA (1) CA3101271A1 (ru)
CL (1) CL2020003033A1 (ru)
CO (1) CO2020014506A2 (ru)
CR (1) CR20200568A (ru)
DK (1) DK3802608T3 (ru)
EA (1) EA202092847A1 (ru)
EC (1) ECSP20075215A (ru)
FI (1) FI3802608T3 (ru)
HR (1) HRP20250621T1 (ru)
IL (1) IL278846A (ru)
JO (1) JOP20200302A1 (ru)
LT (1) LT3802608T (ru)
MA (1) MA52773B1 (ru)
MX (1) MX2020012587A (ru)
NI (1) NI202000089A (ru)
PE (1) PE20210132A1 (ru)
PH (1) PH12020551920A1 (ru)
PT (1) PT3802608T (ru)
SA (1) SA520420631B1 (ru)
SG (1) SG11202011270QA (ru)
TW (1) TW202012443A (ru)
UA (1) UA129050C2 (ru)
UY (1) UY38245A (ru)
WO (1) WO2019224717A2 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CR20200563A (es) 2018-05-24 2021-05-11 Janssen Biotech Inc Agentes aglutinantes de psma y usos de estos
CA3101304A1 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Monospecific and multispecific anti-tmeff2 antibodies and their uses
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MD3823665T2 (ro) 2018-07-19 2024-05-31 Regeneron Pharma Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
EP3956022A1 (en) 2019-04-19 2022-02-23 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
JP2022541332A (ja) 2019-07-26 2022-09-22 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用
CA3164972A1 (en) * 2019-12-18 2021-06-24 Janssen Biotech, Inc. Materials and methods for in vivo biological targeting
CN115484981A (zh) * 2020-02-27 2022-12-16 詹森生物科技公司 用于调节免疫应答的材料和方法
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
CA3184189A1 (en) * 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
AR123083A1 (es) 2020-07-29 2022-10-26 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
JP2023542257A (ja) 2020-09-16 2023-10-05 アムジェン インコーポレイテッド 癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法
TW202216784A (zh) * 2020-09-29 2022-05-01 大陸商信達生物製藥（蘇州）有限公司 抗ｃｄ３抗體以及其用途
IL302277A (en) 2020-10-22 2023-06-01 Janssen Biotech Inc Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
MX2023013714A (es) 2021-05-21 2024-01-16 Leo Pharma As Anticuerpos anti-proteina accesoria del receptor de interleucina 1 (il-1).
PE20240727A1 (es) * 2021-08-27 2024-04-15 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos
US20230073821A1 (en) * 2021-08-27 2023-03-09 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (cov) variants
WO2023178645A1 (zh) * 2022-03-25 2023-09-28 嘉和生物药业有限公司 靶向cd3的抗体及其应用
AU2023345467A1 (en) * 2022-09-21 2025-05-08 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use
AU2023356984A1 (en) 2022-10-05 2025-03-20 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
ATE294860T1 (de) 1997-09-16 2005-05-15 Egea Biosciences Llc Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
NZ701825A (en) 2010-04-20 2016-06-24 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
SG195072A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
PL3653049T3 (pl) 2012-12-14 2024-02-26 Omniab, Inc. Polinukleotydy kodujące przeciwciała gryzoni z ludzkimi idiotypami i zwierzęta je zawierające
KR20250078622A (ko) * 2013-07-05 2025-06-02 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
PE20210648A1 (es) * 2013-12-17 2021-03-26 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
JP6738285B2 (ja) * 2014-05-28 2020-08-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
CN114230668B (zh) * 2015-01-23 2025-07-11 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EA201891084A1 (ru) 2015-11-02 2019-10-31 Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
IL265321B2 (en) 2016-09-14 2024-01-01 Teneobio Inc Cd3 binding antibodies
CN113164588A (zh) * 2018-05-16 2021-07-23 詹森生物科技公司 治疗癌症并增强t细胞重定向治疗剂的功效的方法
CR20200563A (es) 2018-05-24 2021-05-11 Janssen Biotech Inc Agentes aglutinantes de psma y usos de estos
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CA3101304A1 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Monospecific and multispecific anti-tmeff2 antibodies and their uses

Also Published As

Publication number Publication date
MA52773A (fr) 2021-04-14
UA129050C2 (uk) 2025-01-01
HRP20250621T1 (hr) 2025-07-18
WO2019224717A2 (en) 2019-11-28
PT3802608T (pt) 2025-06-27
LT3802608T (lt) 2025-06-25
MX2020012587A (es) 2021-04-28
JP7530299B2 (ja) 2024-08-07
US20230322924A1 (en) 2023-10-12
CN120058941A (zh) 2025-05-30
EP3802608A2 (en) 2021-04-14
EP3802608B1 (en) 2025-04-30
KR20210012007A (ko) 2021-02-02
CN112912397A (zh) 2021-06-04
SG11202011270QA (en) 2020-12-30
US20200048349A1 (en) 2020-02-13
SA520420631B1 (ar) 2023-12-03
IL278846A (en) 2021-01-31
DK3802608T3 (da) 2025-06-10
AU2019274656A1 (en) 2020-11-26
JP2024116190A (ja) 2024-08-27
FI3802608T3 (fi) 2025-06-11
NI202000089A (es) 2021-01-21
WO2019224717A3 (en) 2020-03-05
UY38245A (es) 2019-11-29
CN112912397B (zh) 2025-03-14
AR115422A1 (es) 2021-01-20
MA52773B1 (fr) 2025-05-30
CO2020014506A2 (es) 2020-12-10
CR20200568A (es) 2021-02-26
PH12020551920A1 (en) 2021-06-14
BR112020023508A2 (pt) 2021-03-30
ECSP20075215A (es) 2020-12-31
CA3101271A1 (en) 2019-11-28
US11603405B2 (en) 2023-03-14
WO2019224717A9 (en) 2021-02-04
TW202012443A (zh) 2020-04-01
JP2021524249A (ja) 2021-09-13
PE20210132A1 (es) 2021-01-19
JOP20200302A1 (ar) 2020-11-23
CL2020003033A1 (es) 2021-04-16

Similar Documents

Publication Publication Date Title
EA202092847A1 (ru) Антитела к cd3 и их применение
EA202092839A1 (ru) Агенты, связывающиеся с psma, и виды их применения
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CR20190550A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
SA522431756B1 (ar) Tigit أجسام مضادة لـ
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
EA201891093A1 (ru) Антитела, специфически связывающие pd-1, и их применение
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
MX2021009275A (es) Moleculas de union especificas.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA201891299A1 (ru) Терапевтические антитела к cd9
EA202090617A1 (ru) Варианты антител
EA202090727A1 (ru) Варианты антител
EA201992186A1 (ru) Антитела к par2 и пути их применения
EA201992747A1 (ru) Антитела к fam19a5 и их применение
EA201992885A1 (ru) Антитела, специфически связывающиеся с pd-1, и способы их применения
EA202092279A1 (ru) Антитела к mica и/или micb и их применение
EA201992886A1 (ru) Активируемые антитела против pdl1 и способы их применения